• 1
    American Cancer Society. Cancer Facts and Figures 2004. Atlanta: American Cancer Society, 2004.
  • 2
    Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 136571.
  • 3
    Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 16037.
  • 4
    Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1973–1997. Bethesda, MD: National Cancer Institute, 2000.
  • 5
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 75967.
  • 6
    Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 1025.
  • 7
    Hasegawa Y, Takeda S, Ichii S, et al. Detection of k-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 1995; 10: 14415.
  • 8
    Smith-Raven J, England J, Talbot IC, et al. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995; 36: 816.
  • 9
    Villa E, Dugani A, Rebecchi AM, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110: 134653.
  • 10
    Nollau P, Moser C, Weinland G, et al. Detection of K-ras mutations in stools of patients with colorectal cancers by mutant-enriched PCR. Int J Cancer 1996; 66: 3326.
  • 11
    Eguchi S, Kohara N, Komuta K, et al. Mutations of the p53 gene in stool of patients with respectable colorectal cancer. Cancer 1996; 77: 170710.
  • 12
    Puig P, Urgell E, Capella G, et al. Detection of k-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 356873.
  • 13
    Thompson MR, Heath I, Ellis BG, et al. Identifying and managing patients at low risk of bowel cancer in general practice. BMJ 2003; 327: 2635.
  • 14
    Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 14727.
  • 15
    Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 146771.
  • 16
    Lieberman DA, Weiss DG, Bong JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. VA Cooperative Study Group 380. N Engl J Med 2000; 343: 1628.
  • 17
    Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 1559.
  • 18
    Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001; 175: 1958.
  • 19
    Selby JV, Friedman GD, Quesenberry CP Jr, et al. A case control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 6537.
  • 20
    Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 15725.
  • 21
    Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155: 17418.
  • 22
    Kavanagh AM, Giovannucci EL, Fuchs CS, et al. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control 1998; 9: 45562.
  • 23
    Leard LE, Savides TJ, Ganiats TG. Patient preferences for colorectal cancer screening. J Fam Pract 1997; 45: 2058.
  • 24
    Weissfeld JL, Ling BS, Schoen RE, et al. Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2002; 94: 256976.
  • 25
    Imperiale TF, Wagner DR, Lin CY, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 16974.
  • 26
    Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 55560.
  • 27
    Winawer SJ, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale – update based on new evidence. Gastroenterology 2003; 124: 54460.
  • 28
    Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000; 342: 114955.
  • 29
    Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians Network. N Engl J Med 2000; 342: 115662.
  • 30
    Von Stolk RU, Beach M, Baron JA, et al. for the Polyp Prevention Study Group. Incidence of colorectal cancer during colonoscopic surveillance in a four year polyp prevention trial. Gastroenterology 1998; 114: A697 (abstract).
  • 31
    Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 197781.
  • 32
    Fenlon HM, Nunes DP, Schroy PC III, et al. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. N Engl J Med 1999; 341: 1496503.
  • 33
    Yee J, Akerkar GA, Hung RK, et al. Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients. Radiology 2001; 219: 68592.
  • 34
    Johnson DC, Harmsen WS, Wilson LA, et al. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology 2003; 125: 3119.
  • 35
    Cotton PB, Durkalski VL, Palesch YY, et al. Virtual colonoscopy: final results from a multicenter study. Gastrointest Endosc 2003; 57: AB174 (abstract).
  • 36
    Zalis M, Perumpillichira J, Hur C, et al. Digital subtraction bowel cleansing (DSBC) in CT colonography (CTC): experience in 70 patients. Gastroenterology Suppl 2003; 124: A114.
  • 37
    Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 49: 2191200.
  • 38
    Iyengar V, Albaugh G, Lohani A, et al. Human stools as a source of viable colonic epithelial cells. FASEB J 1991; 5: 28569.
  • 39
    Loktinonov A, O'Neill IK, Sylvester KR, et al. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998; 4: 3374.
  • 40
    Boland CR, Sato J, Saito K, et al. Genetic instability and chromosomal aberrations in colorectal cancer: a review of current models. Cancer Detect Prev 1998; 22: 37782.
  • 41
    Tobi M, Prabhu S, Gage RE, et al. Colorectal cancer risk: the impact of evidence of a field effect of carcinogenesis on blinded diagnosis using an anti-adenoma antibody test performed on colonoscopic effluent. Dig Dis Sci 2002; 47: 31721.
  • 42
    Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 2357.
  • 43
    Hermsen M, Postma C, Baak J, et al. Colorectal adenoma to carcinoma progression follows multiple pathways to chromosomal instability. Gastroenterology 2002; 123: 110919.
  • 44
    Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Nat Acad Sci USA 2000; 97: 7105.
  • 45
    Hofseth LJ, Khan MA, Ambrose M, et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest 2003; 112: 188794.
  • 46
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319: 52532.
  • 47
    Alhquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 121927.
  • 48
    Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54: 55236.
  • 49
    Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995; 108: 43440.
  • 50
    Zhu P, Keohavong P, Finkelstein SD, et al. K-ras gene mutation in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997; 57: 248592.
  • 51
    Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 485578.
  • 52
    Sheikh RA, Hee Min B, Yasmeen S, et al. Correlation of Ki-67, p53, and Adnab-9 immunohistochemical staining and ploidy with clinical and histopathologic features of severely dysplastic colorectal adenomas. Dig Dis Sci 2003; 48: 2239.
  • 53
    Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 31120.
  • 54
    Glebov OK, Rodriguez LM, Nakahara K, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol, Biomarkers Prev 2003; 12: 75562.
  • 55
    Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359: 4034.
  • 56
    Boynton KA, Summerhayes IC, Ahlquist DA, et al. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 105865.
  • 57
    Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 4753.
  • 58
    Calistri D, Rengucci C, Bocchini R, et al. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003; 1: 37783.
  • 59
    Traverso G, Diehl F, Hurst R, et al. Multicolor in vitro translation. Nat Biotechnol 2003; 21: 10937. Epub 2003 Aug 10.
  • 60
    Dianxu F, Shengdao Z, Tianquan H, et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19–9 analysis. Pancreas 2002; 25: 33641.
  • 61
    De Kok JB, van Solinge WW, Ruers TJ, et al. Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest 1997; 57: 6014.
  • 62
    Kopreski MS, Benko FA, Kwee C, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997; 76: 12939.
  • 63
    Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62: 3715.
  • 64
    Bearzatto A, Conte D, Frattini M, et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002; 8: 37827.
  • 65
    Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 39668.
  • 66
    Syngal S, Chung D, Willet C, et al. The loss of stool DNA mutation abnormalities in colorectal neoplasia after treatment. Gastroenterol Suppl 2003; 124: A5 (abstract).
  • 67
    Brand RE, Shuber AP, Laken SJ, et al. Reliability of a stool DNA mutation specific assay for colorectal cancer. Gastroenterol Suppl 2002; 122: A-479.
  • 68
    Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 85865.